Sun Pharma Q2 Results: Net profit jumps 28% to Rs 3,040 crore on higher sales

Sun Pharma reported a 28% year-on-year (YoY) jump in net profit to Rs 3040 crore in Q2FY25 led by higher sales growth in domestic formulation and global specialty portfolio.

The company reported net profit of Rs 2375.5 crore during the corresponding quarter of the previous year.

Revenue rose 10.5% YoY to Rs. 13,264 crore in Q2FY25.

The earnings for interest, tax, depreciation and ammortisation (EBITDA) rose 23.9% to Rs. 3939 crore in Q2, and EBITDA margins gained 350 basis points YoY to 29.6%.

India formulation sales rose 11% YoY to Rs. 4265.2 crore in Q2FY25. India accounts for 32% of Sun Pharma sales.

Sun Pharma holds 8.1% market share and is ranked number one in the Rs. 2.17 lakh crore Indian pharmaceutical market as per AIOCD AWACS MAT September 2024 report.In Q2FY25, the company launched 14 new products in the Indian market.The US formulation sales grew 20.3% YoY to 4327.4 crore.

US formulation sales accounted for 33% of consolidated sales.

Global specialty sales stood at $286 million, up 19.2% YoY in Q2FY25.

Emerging markets formulation sales grew 3.2% YoY to Rs 2452 crore, rest-of-the-world (RoW) formulation sales were down 3.5% YoY to Rs 1663 crore.

R&D expenses rose 2.5% YoY to Rs 793 crore in Q2FY25.